截至2025年8月22日收盘，昂利康股价报50.56元，较前一交易日下跌1.56%。当日成交额达4.33亿元， 换手率为4.64%。 昂利康属于化学制药板块，公司主营业务为医药产品的研发、生产和销售。作为创新药概念股，公司产 品涵盖抗感染类、心血管类、消化系统类等多个治疗领域。 近期创新药行业迎来多项政策支持。国家医保局与卫健委7月初印发《支持创新药高质量发展的若干措 施》，提出增设商业健康保险创新药品目录，支持创新药进入医保目录和商业保险创新药品目录。此 外，创新药出海也取得进展，多家药企与跨国药企达成合作协议。 资金流向方面，8月22日昂利康主力资金净流入365.83万元，近五日主力资金净流入1.35亿元。 风险提示：股市有风险，投资需谨慎。 ...

Group 1 - The stock price of Luoxin Pharmaceutical is reported at 5.95 yuan as of August 6, 2025, reflecting a decline of 1.49% from the previous trading day [1] - The trading volume on the same day reached 725,895 hands, with a total transaction amount of 435 million yuan, and a price fluctuation of 5.30% [1] - Luoxin Pharmaceutical operates in the chemical pharmaceutical industry, focusing on drug research, production, and sales, with product lines including anti-infection, digestive system, and respiratory system medications [1] Group 2 - The number of shareholders in Luoxin Pharmaceutical significantly increased by 31,700 from July 18 to July 31, 2025, marking a growth rate of 88.04% [1] - As of July 31, 2025, the total number of shareholders reached 67,800, with an average market value of circulating shares held by each shareholder at 104,200 yuan [1] - On August 6, 2025, the net outflow of main funds for Luoxin Pharmaceutical was 26.09 million yuan, with a cumulative net outflow of 22.39 million yuan over the past five days [1]

罗欣药业属于化学制药行业，公司主营业务涵盖医药产品的研发、生产和销售。公司产品线包括抗感染 类、消化系统类、呼吸系统类等药品。 罗欣药业8月4日股价报收6.13元，较前一交易日下跌0.22元，跌幅3.46%。当日开盘价为6.23元，最高触 及6.53元，最低下探6.03元，成交量为108.18万手，成交金额6.72亿元。 风险提示：股市有风险，投资需谨慎。 8月4日盘中，罗欣药业出现快速波动。早盘9点36分出现快速反弹，5分钟内涨幅超过2%，报6.5元；随 后在9点43分又快速回调，5分钟内跌幅超过2%，报6.26元。 资金流向方面，8月4日主力资金净流入1317.26万元，占流通市值比例为0.2%。近五个交易日累计主力 资金净流入2533.91万元，占流通市值比例为0.38%。 ...